Discovery of a Series of Efficient, Centrally Efficacious BACE1 Inhibitors through Structure-Based Drug Design
Christopher R. Butler(Pfizer (United States)), Brian T. O’Neill(Pfizer (United States)), Gabriela Barreiro(Pfizer (United States)), Michael A. Brodney(Vertex Pharmaceuticals (United States)), Cathleen Gonzales, David Riddell(Eli Lilly (United States)), Kevin Parris, Feng Pan(Pfizer (United States)), Luis Martinez-Alsina(Pfizer (United States)), Christopher J. Helal(Pfizer (United States)), Elizabeth Beck(Pfizer (United States)), Leanne M. Buzon(Pfizer (United States)), Kevin Ogilvie(Pfizer (United States)), Charles E. Nolan(Pfizer (United States)), Shawn D. Doran(Pfizer (United States)), Jinlong Wang(WuXi AppTec (China)), Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), John C. Murray(Pfizer (United States)), Ashley Robshaw(Pfizer (United States)), F.F. Vajdos(University of Utah), Yong Zhang(Ministry of Education of the People's Republic of China), Ricardo Lira(Pfizer (United States)), Joseph M. Young(Pfizer (United States)), Alison H. Varghese(Pfizer (United States)), Jason K. Dutra(Pfizer (United States))
Cited by 46
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351